Home › Research › Disease mechanisms
Scalable human neuronal models of tauopathy producing endogenous seed-competent 4R tau
Eliona Tsefou, Sumi Bez, Timothy J.Y. Birkle, Martha S. Foiani, Naoto Watamura, Mathieu Bourdenx, Daria Gavriouchkina, Emir Turkes et al.. Science Advances, 2026-07-31
Topic: Brain proteins, microglia and lab models
Abstract The accumulation of pathological four-repeat (4R) tau is central to several frontotemporal dementia (FTD) subtypes, but human neuronal models amenable to high-throughput screening of 4R tau-targeting therapies remain very limited. To address this, we developed iPSC-derived i 3 Neuron (i 3 N) lines expressing >75% 4R tau, driven by FTD splice-shifting mutations (S305N or S305N/IVS10+3). These neurons develop hyperphosphorylated tau and demonstrate somatodendritic mis-localization. Unlike other stem cell models of tauopathy, these i 3 N neurons develop endogenous seed-competent tau and present pFTAA-positive tau assemblies after 28 days in culture. For scalable screening, we CRISPR-engineered a HiBiT luminescence tag at the endogenous MAPT locus into the S305N/IVS10+3 iPSC line, enabling precise quantification of tau levels and pharmacological responses. The model responded predictably to compounds affecting tau clearance, demonstrating its suitability for drug discovery. Overall, this i 3 N platform recapitulates key features of 4R tauopathy and provides a robust system to identify therapeutic modulators of pathological tau.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Tsefou, E., Bez, S., Birkle, T. J., Foiani, M. S., Watamura, N., Bourdenx, M., et al. (2026). Scalable human neuronal models of tauopathy producing endogenous seed-competent 4R tau. Science Advances. https://doi.org/10.1126/sciadv.aeg1445
Vancouver
Tsefou E, Bez S, Birkle TJ, Foiani MS, Watamura N, Bourdenx M, et al. Scalable human neuronal models of tauopathy producing endogenous seed-competent 4R tau. Science Advances. 2026. doi:10.1126/sciadv.aeg1445. PMID: 42536730.
BibTeX
@article{tsefou2026-42536730,
author = {Tsefou, Eliona and Bez, Sumi and Birkle, Timothy J.Y. and Foiani, Martha S. and Watamura, Naoto and Bourdenx, Mathieu and Gavriouchkina, Daria and Turkes, Emir and others},
title = {{Scalable human neuronal models of tauopathy producing endogenous seed-competent 4R tau}},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aeg1445},
pmid = {42536730},
url = {https://doi.org/10.1126/sciadv.aeg1445}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Overall, this i 3 N platform recapitulates key features of 4R tauopathy and provides a robust system to identify therapeutic modulators of pathological tau.
Why it matters
Researchers developed iPSC-derived neuron lines that express mostly 4R tau and develop hyperphosphorylated, mis-localized and seed-competent tau, and engineered one line to allow precise measurement of tau levels and drug responses. This is a laboratory model for drug discovery, not a treatment, cure or prevention for patients.
Study details
- Evidence strengthLow
How this study scored 40/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Science Advances) |
| Journal's citation record | 3 / 4 | Science Advances: journal h-index 378 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 3 / 6 | Cited 4.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Karen Duff: h-index 96 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 42536730) |
| Free to read | 2 / 2 | Free to read |
| Total | 40 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Disease mechanisms
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.